Dr Reddy's Laboratories (DRL) declined 1.07% to Rs 1200.95 after the US Food and Drug Administration (USFDA) concluded its Good manufacturing practice (GMP) inspection with seven observations at API manufacturing facility in Bollaram, Hyderabad.
The GMP inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issued Form-483 with 7 observations.Dr Reddy's Labs is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.
The companys consolidated net profit declined 15.3% to Rs 1255.70 crore despite of 16.5% jump in revenue from operations to Rs 8016.10 crore in Q2 FY25 over Q2 FY24.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content